Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma

Li, Sha; Xue, Peng; Diao, Xun; Fan, Qi-Yu; Ye, Kun; Tang, Xiaomei; Liu, Jia; Huang, Zhong-Yan; Tang, Qing-Hai; Jia, Chengyou; Xin, Rui; Lv, Zhongwei; Liu, Ji‐Bin; Ma, Yu‐Shui; Fu, Da

doi:10.1016/j.jare.2023.01.010

Cited by 10 publications

(2 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a generally acknowledged cell cycle-related gene, we found that CDKN3 is correlated with cell cycle-associated pathways in almost all types of cancers. For example, E2F, MYC, and mTOR, which have been found to regulate cell cycle progression and cell proliferation, [64][65][66] were strongly positively correlated with CDKN3 in our results. However, we also found some new noncell cycle-correlated pathways.…”

supporting

confidence: 65%

Comprehensive Analysis Reveals the Potential Roles of CDKN3 in Pancancer and Verification in Endometrial Cancer

Gao,

Fan,

Liu

et al. 2023

IJGM

View full text Add to dashboard Cite

Background: Cyclin-dependent kinase inhibitor 3 (CDKN3) has been studied in many cancers. However, the comprehensive and systematic pancancer analysis of CDKN3 genes is still lacking. Methods: Data were downloaded from online databases. R was used for analysis of the differential expression and gene alteration of CDKN3 and of the associations between CDKN3 expression and survival, signaling pathways, and drug sensitivity. Clinical samples and in vitro experiments were selected for verification. Results: CDKN3 expression was higher in most types of cancers, and this phenotype was significantly correlated with poor survival. CDKN3 showed gene alterations and copy number alterations in many cancers and associated with some immune-related pathways and factors. Drug sensitivity analysis elucidated that CDKN3 could be a useful marker for therapy selection. Clinical samples elucidated CDKN3 expressed high in endometrial cancer tissue. In vitro studies showed that CDKN3 induced pro-tumor effect in immune environment and facilitated endometrial cancer cell proliferation and G1/S phase transition. Conclusion: CDKN3 has been shown to be highly expressed in most types of cancers and promoted cancer cell progression. CDKN3 may serve as a novel marker in clinical diagnosis, treatment, and prognosis prediction in future.

show abstract

supporting

confidence: 65%

Comprehensive Analysis Reveals the Potential Roles of CDKN3 in Pancancer and Verification in Endometrial Cancer

Gao,

Fan,

Liu

et al. 2023

IJGM

View full text Add to dashboard Cite

show abstract

“…CDKN3 overexpression is linked to high MYC expression and is associated with a poor prognosis. Upregulation of this gene has been recently reported to significantly correlate with hypomethylated promoter status, advanced T stage, metastasis, and aberrant antitumor immunity in cancer patients [27].…”

Section: Discussionmentioning

confidence: 98%

A Blood-Based Immune Gene Signature with Prognostic Significance in Localized Prostate Cancer

Fortis

Batsaki

Stokidis

et al. 2023

Cancers

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the most common male cancers worldwide and one of the deadliest if unsuccessfully treated. Τhe need for reliable, easily accessible immune-related molecular biomarkers that could be combined with clinically defined criteria, including PSA and Gleason score, to accurately predict PCa patients’ clinical outcomes is emerging. Herein, we describe for the first time a blood-identified immune-related gene signature comprising eight upregulated multi-functional genes associated with poor prognosis. Next-generation sequencing (NGS) analysis of PCa patients’ peripheral blood samples revealed a more than three-fold upregulation of each of the eight genes as compared to samples originating from healthy donors. The construction of gene and protein interaction networks revealed different extents of the functional implications of these genes in the regulation of cell proliferation and immune responses. Analysis of the available data from The Cancer Genome Atlas (TCGA) regarding gene expression and survival of prostate adenocarcinoma (PRAD) and pan-cancer (PANCAN) patients revealed that intra-tumoral upregulation of this eight-gene signature (8-GS) was associated with poor 5-year progression-free intervals in PCa patients, even in those with high Gleason scores, and also with an unfavorable prognosis for cancer patients irrespective of the cancer type and even in the early stages. These observations suggest that further investigation of the 8-GS prospectively in randomized clinical trials, in which clinical benefit in terms of evaluating time to disease progression can be assessed, is warranted.

show abstract

Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application

Su,

Bu,

et al. 2024

Clinical & Translational Med

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a primary malignant tumour, ranking second in global mortality rates and posing significant health threats. Epigenetic alterations, particularly DNA methylation, have emerged as pivotal factors associated with HCC diagnosis, therapy, prognosis and malignant progression. However, a comprehensive analysis of the DNA methylation mechanism driving HCC progression and its potential as a therapeutic biomarker remains lacking. This review attempts to comprehensively summarise various aspects of DNA methylation, such as its mechanism, detection methods and biomarkers aiding in HCC diagnosis, treatment and prognostic assessment of HCC. It also explores the role of DNA methylation in regulating HCC's malignant progression and sorafenib resistance, alongside elaborating the therapeutic effects of DNA methyltransferase inhibitors on HCC. A detailed examination of these aspects underscores the significant research on DNA methylation in tumour cells to elucidate malignant progression mechanisms, identify diagnostic markers and develop new tumour‐specific inhibitors for HCC.Key points A comprehensive summary of various aspects of DNA methylation, such as its mechanism, detection methods and biomarkers aiding in diagnosis and treatment. The role of DNA methylation in regulating hepatocellular carcinoma's (HCC) malignant progression and sorafenib resistance, alongside elaborating therapeutic effects of DNA methyltransferase inhibitors. Deep research on DNA methylation is critical for discovering novel tumour‐specific inhibitors for HCC.

show abstract

Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma

Cited by 10 publications

References 68 publications

Comprehensive Analysis Reveals the Potential Roles of CDKN3 in Pancancer and Verification in Endometrial Cancer

Comprehensive Analysis Reveals the Potential Roles of CDKN3 in Pancancer and Verification in Endometrial Cancer

A Blood-Based Immune Gene Signature with Prognostic Significance in Localized Prostate Cancer

Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application

Contact Info

Product

Resources

About